Perrigo’s ProAir Rival ‘Unlikely To Be Back In 2021’ Following Recall
Q3 2020 Recall Led To $200m Impairment Charge
Perrigo has moved to allay more serious concerns around its generic ProAir inhaler device, but concedes that it is highly unlikely the lucrative respiratory product will return to the market this year.
You may also be interested in...
Perrigo says its deal to divest its Rx business remains “on track,” with the company shunting the prescription unit into “discontinued operations” in the first quarter as it trains its focus on the firm’s future growth engine of consumer self-care.
Sandoz has struck a US deal to in-license both branded Proventil HFA and an authorized generic version of the albuterol sulfate product from Kindeva Drug Delivery. The deal comes after a busy year for generic versions of albuterol that have transformed the market dynamics for the respiratory treatment.
Perrigo has finally found the right deal to secure the long-awaited divestment of its prescription business, reaching an agreement worth just over $1.5bn with private equity firm Altaris Capital Partners.